Nonneoplastic and Neoplastic Pituitary Diseases

  • Christine B. Warren Baran
  • Richard A. Prayson
Part of the Molecular Pathology Library book series (MPLB, volume 3)


The role of molecular testing in the routine evaluation of pituitary disease is in its infancy. There is currently a very limited role for such testing in the routine clinical evaluation of pituitary lesions. Research studies using molecular techniques is augmenting our understanding of pituitary disease and particularly neoplastic lesions. This chapter provides an overview of the interface between molecular pathology and both nonneoplastic and neoplastic conditions of the pituitary gland.


Growth Hormone Pituitary Adenoma Pituitary Tumor Granular Cell Tumor Pituitary Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Missler V, Mack M, Nowack G, et al. Pituitary sarcoidosis. Klin Wochenschr. 1990;68:342–345.PubMedCrossRefGoogle Scholar
  2. 2.
    Gartman JJ Jr, Powers SK, Fortune M. Pseudotumor of the sellar and parasellar areas. Neurosurgery. 1989;24:896–901.PubMedCrossRefGoogle Scholar
  3. 3.
    Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab. 1995;80:2302–2311.PubMedCrossRefGoogle Scholar
  4. 4.
    Pastell RG, Best JD, Alford FP. Lymphocytic hypophysitis. The clinical spectrum of the disorder and evidence for an autoimmune pathogenesis. Clin Endocrinol. 1990;33:457–466.Google Scholar
  5. 5.
    Beressi N, Beressi J-P, Cohen R, Modigliani E. Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris). 1999;150:327–341.Google Scholar
  6. 6.
    Bergeron C, Kovacs K, Bilbao SM. Primary “empty sella”. A histologic and immunologic study. Arch Intern Med. 1979;139:248–249.PubMedCrossRefGoogle Scholar
  7. 7.
    Bergland RM, Ray BS, Torack RM. Anatomical variations in the pituitary gland and adjacent structures in 225 human autopsy cases. J Neurosurg. 1968;28:93–99.PubMedCrossRefGoogle Scholar
  8. 8.
    Barrow DL, Spector RH, Takei Y, Tindall GT. Symptomatic Rathke’s cleft cysts located entirely in the suprasellar region: review of diagnosis, management and pathogenesis. Neurosurgery. 1985;16:766–772.PubMedCrossRefGoogle Scholar
  9. 9.
    Keyaki A, Hirano A, Llena JF. Asymptomatic and symptomatic Rathke’s cleft cysts. Histological study of 45 cases. Neurol Med Chir (Tokyo). 1989;29:88–93.CrossRefGoogle Scholar
  10. 10.
    Steinberg GK, Koenig GH, Golden JB. Symptomatic Rathke’s cleft cysts. Report of two cases. J Neurosurg. 1982;56:290–295.PubMedCrossRefGoogle Scholar
  11. 11.
    Ikeda H, Yoshimoto T. Clinicopathological study of Rathke’s cleft cysts. Clin Neuropathol. 2002;21:82–91.PubMedGoogle Scholar
  12. 12.
    Lundardi P, Missori P, Gagliardi FM, Fortuna A. Dermoid cysts of the posterior cranial fossa in children. Report of nine cases and review of the literature. Surg Neurol. 1990;34:39–42.CrossRefGoogle Scholar
  13. 13.
    Yamakawa K, Shitara N, Genka S, Manaka S, Takakura K. Clinical course and surgical prognosis of 33 cases of intracranial epidermoid tumors. Neurosurgery. 1989;24:568–573.PubMedCrossRefGoogle Scholar
  14. 14.
    Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer. 1976;37:1944–1952.PubMedCrossRefGoogle Scholar
  15. 15.
    Van Effenterre R, Boch AL. Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg. 2002;97:3–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Giangaspero F, Burger PC, Osborne DR, Stein RB. Suprasellar papillary squamous epithelioma (“papillary craniopharyngioma”). Am J Surg Pathol. 1984;8:57–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995;83:206–214.PubMedCrossRefGoogle Scholar
  18. 18.
    Nishi T, Kuratsu J, Takeshima H, Saito Y, Kochi M, Ushio Y. Prognostic significance of the MIB-1 labeling index for patients with craniopharyngioma. Int J Mol Med. 1999;3:157–161.PubMedGoogle Scholar
  19. 19.
    Rickert CH, Paulus W. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas. J Neurol Neurosurg Psych. 2003;74:260–261.CrossRefGoogle Scholar
  20. 20.
    Hofmann BM, Kreutzer J, Saeger W, et al. Nuclear beta-catenin accumulation as reliable marker for the differentiation between cystic craniopharyngiomas and Rathke cleft cells: a clinico-pathologic approach. Am J Surg Pathol. 2006;30:1595–1603.PubMedCrossRefGoogle Scholar
  21. 21.
    Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 2002;161:1997–2001.PubMedGoogle Scholar
  22. 22.
    Ezzat S, Asa SL, Stefaneanu L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab. 1994;78:555–560.PubMedCrossRefGoogle Scholar
  23. 23.
    Al-Gahtany M, Horvath E, Kovacs K. Pituitary hyperplasia. Hormones (Athens). 2003;2:149–158.Google Scholar
  24. 24.
    Horvath E, Kovacs K, Scheithauer BW. Pituitary hyperplasia. Pituitary. 1999;1:169–179.PubMedCrossRefGoogle Scholar
  25. 25.
    Scheithauer BW, Horvath E, Randall RV, Kovacs K. Pituitary hyperplasia. Pathol Res Pract. 1998;3:281–289.Google Scholar
  26. 26.
    Kleinschmidt-DeMasters BK. Subtyping does matter in pituitary adenomas. Acta Neuropathol. 2006;111:84–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Asa SL, Ezzat S. Molecular basis of pituitary development and cytogenesis. Front Horm Res. 2004;32:1–19.PubMedCrossRefGoogle Scholar
  28. 28.
    Lamolet B, Pulichino AM, Lamonerie T, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 2001;104:849–859.PubMedCrossRefGoogle Scholar
  29. 29.
    Lamonerie T, Tremblay JJ, Lanctot C, Therrien M, Gauthier Y, Drouin J. Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev. 1996;10:1284–1295.PubMedCrossRefGoogle Scholar
  30. 30.
    Poulin G, Turgeon B, Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol. 1997;17:6673–6682.PubMedGoogle Scholar
  31. 31.
    Mangalam HJ, Albert VR, Ingraham HA, et al. A pituitary POU domain protein, Pit-1, activates both growth hormone and prolactin promoters transcriptionally. Genes Dev. 1989;3:946–958.PubMedCrossRefGoogle Scholar
  32. 32.
    Simmons DM, Voss JW, Ingraham HA, et al. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation and synergistic interactions with other classes of transcription factors. Genes Dev. 1990;4:695–711.PubMedCrossRefGoogle Scholar
  33. 33.
    Day RN, Koike S, Sakai M, Muramatsu M, Maurer RA. Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene. Mol Endocrinol. 1990;4:1964–1971.PubMedCrossRefGoogle Scholar
  34. 34.
    Scully KM, Rosenfeld MG. Pituitary development: regulatory codes in mammalian organogenesis. Science. 2002;295:2231–2235.PubMedCrossRefGoogle Scholar
  35. 35.
    Frawley LS, Boockfor FR. Mammosomatotropes: presence and functions in normal and neoplastic pituitary tissue. Endocr Rev. 1991;12:337–355.PubMedCrossRefGoogle Scholar
  36. 36.
    Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 1996;81:2165–2170.PubMedCrossRefGoogle Scholar
  37. 37.
    Lloyd R. Tumors of the pituitary gland. In: DeLellis RA, Lloyd R, Heitz PU, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumors of Endocrine Organs. Lyons: IARC; 2004:9–48.Google Scholar
  38. 38.
    Laws ER Jr, Lopes MB. The new WHO classification of pituitary tumors: highlights and areas of controversy. Acta Neuropathol. 2006;111:80–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Snyder PJ. Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am. 1993;22:163–175.PubMedGoogle Scholar
  40. 40.
    Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169:575–581.PubMedGoogle Scholar
  41. 41.
    Horvath E, Kovacs K. Pathology of prolactin cell adenomas of the human pituitary. Semin Diagn Pathol. 1986;3:4–17.PubMedGoogle Scholar
  42. 42.
    Kovacs K, Stefaneanu L, Horvath E, et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol. 1991;418:439–446.PubMedCrossRefGoogle Scholar
  43. 43.
    Asa SL. Tumors of the Pituitary Gland. Washington, DC: Armed Forces Institute of Pathology; 1998.Google Scholar
  44. 44.
    Rocken C, Uhlig H, Saeger W, Linke RP, Fehr S. Amyloid deposits in pituitaries and pituitary adenomas: immunohistochemistry and in situ hybridization. Endocr Pathol. 1995;6:135–143.PubMedCrossRefGoogle Scholar
  45. 45.
    Thorner MO. The anterior pituitary. In: Wilson JD, Foster DW, Kronenberg HM, eds. Williams Textbook of Endocrinology. Philadelphia: WB Saunders; 1998:249–340.Google Scholar
  46. 46.
    Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer. 1996;78:502–510.PubMedCrossRefGoogle Scholar
  47. 47.
    Neumann PE, Goldman JE, Horoupian DS, Hess MA. Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med. 1985;109:505–508.PubMedGoogle Scholar
  48. 48.
    Saeger W, Wilczak W, Ludecke DK, Buchfelder M, Fahlbusch R. Hormone markers in pituitary adenomas: changes within last decade resulting from improved method. Endocr Pathol. 2003;14(1):49–54.PubMedCrossRefGoogle Scholar
  49. 49.
    Tallen G, Fehr S, Saeger W, Uhlig H, Ludecke DK. Detection of growth hormone, prolactin and human beta-chorionic gonadotropin mRNA in growth hormone-secreting pituitary adenomas and in prolactin-secreting pituitary adenomas by in situ hybridization using a non-isotopic detection method. Acta Endocrinol. 1993;128:411–417.PubMedGoogle Scholar
  50. 50.
    Al-Brahim NY, Asa SL. My approach to pathology of the pituitary gland. J Clin Pathol. 2006;59:1245–1253.PubMedCrossRefGoogle Scholar
  51. 51.
    Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab. 1994;79:113–118.PubMedCrossRefGoogle Scholar
  52. 52.
    Kovacs K, Horvath E. Pathology of growth hormone-producing tumors of the human pituitary. Semin Diagn Pathol. 1986;3:18–33.PubMedGoogle Scholar
  53. 53.
    Yamada S, Aiba T, Sano T, et al. Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery. 1993;33:20–27.PubMedCrossRefGoogle Scholar
  54. 54.
    Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG. Progression of a Nelson’s adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest. 1999;22:70–75.PubMedGoogle Scholar
  55. 55.
    Scheithauer BW, Jaap AJ, Horvath E, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47:723-729. discussion 729–730.PubMedCrossRefGoogle Scholar
  56. 56.
    Stefaneanu L, Kovacs K, Horvath E, Lloyd RV. In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas. Virchows Arch A Pathol Anat Histopathol. 1991;419:107–113.PubMedCrossRefGoogle Scholar
  57. 57.
    Kurosaki M, Saeger W, Ludecke DK. Pituitary tumors in the elderly. Pathol Res Pract. 2001;197:493–497.PubMedCrossRefGoogle Scholar
  58. 58.
    George DH, Scheithauer BW, Kovacs K, et al. Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330–1336.PubMedCrossRefGoogle Scholar
  59. 59.
    Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr. Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery. 2003;53:1076-1084. discussion 1084–1075.PubMedCrossRefGoogle Scholar
  60. 60.
    Mindermann T, Wilson CB. Thyrotropin-producing pituitary adenomas. J Neurosurg. 1993;79:521–527.PubMedCrossRefGoogle Scholar
  61. 61.
    Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. 1986;65:733–744.PubMedCrossRefGoogle Scholar
  62. 62.
    Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg. 2000;93:194–200.PubMedCrossRefGoogle Scholar
  63. 63.
    Young WF Jr, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc. 1996;71:649–656.PubMedCrossRefGoogle Scholar
  64. 64.
    Lopes B. Tumors of the pituitary gland. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors, vol. 2. Philadelphia: Churchill Livingstone Elsevier; 2007:971–996.Google Scholar
  65. 65.
    Labat-Moleur F, Trouillas J, Seret-Begue D, Kujas M, Delisle MB, Ronin C. Evaluation of 29 monoclonal and polyclonal antibodies used in the diagnosis of pituitary adenomas. A collaborative study from pathologists of the Club Francais de l’Hypophyse. Pathol Res Pract. 1991;187:534–538.PubMedGoogle Scholar
  66. 66.
    Asa SL, Kovacs K. Clinically non-functioning human pituitary adenomas. Can J Neurol Sci. 1992;19:228–235.PubMedGoogle Scholar
  67. 67.
    Losa M, Mortini P, Barzaghi R, Franzin A, Giovanelli M. Endocrine inactive and gonadotroph adenomas: diagnosis and management. J Neurooncol. 2001;51:16–177.Google Scholar
  68. 68.
    Zhuang Z, Ezzat SZ, Vortmeyer AO, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 1997;57:5446–5451.PubMedGoogle Scholar
  69. 69.
    Boikos SA, Stratakis CA. Pituitary pathology in patients with Carney Complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary. 2006;9:203–209.PubMedCrossRefGoogle Scholar
  70. 70.
    Daly AF, Jaffrain-Rea ML, Beckers A. Clinical and genetic features of familial pituitary adenomas. Horm Metab Res. 2005;37:347–354.PubMedCrossRefGoogle Scholar
  71. 71.
    Akintoye SO, Chebli C, Booher S, et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab. 2002;87:5104–5112.PubMedCrossRefGoogle Scholar
  72. 72.
    Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum Mol Genet. 2007;16:R73-R79.PubMedCrossRefGoogle Scholar
  73. 73.
    Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312:1228–1230.PubMedCrossRefGoogle Scholar
  74. 74.
    Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 2006;91:3316–3323.PubMedCrossRefGoogle Scholar
  75. 75.
    Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:465–470.PubMedCrossRefGoogle Scholar
  76. 76.
    Thakker RV. Multiple endocrine neoplasia - syndromes of the twentieth century. J Clin Endocrinol Metab. 1998;83:2617–2620.PubMedCrossRefGoogle Scholar
  77. 77.
    Lopes MB, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine. 2005;28:115–121.PubMedCrossRefGoogle Scholar
  78. 78.
    Lubke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol. 1995;141:81–92.PubMedGoogle Scholar
  79. 79.
    Saeger W, Lubke D. Pituitary carcinomas. Endocr Pathol. 1996;7:21–35.PubMedCrossRefGoogle Scholar
  80. 80.
    Gaffey TA, Scheithauer BW, Lloyd RV, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg. 2002;96:352–360.PubMedCrossRefGoogle Scholar
  81. 81.
    Cai WY, Alexander JM, Hedley-Whyte ET, et al. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab. 1994;78:89–93.PubMedCrossRefGoogle Scholar
  82. 82.
    Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002;87:2635–2643.PubMedCrossRefGoogle Scholar
  83. 83.
    Musat M, Vax VV, Borboli N, et al. Cell cycle dysregulation in pituitary oncogenesis. Front Horm Res. 2004;32:34–62.PubMedCrossRefGoogle Scholar
  84. 84.
    Rickert CH, Scheithauer BW, Paulus W. Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol. 2001;102:117–120.PubMedGoogle Scholar
  85. 85.
    Landman RE, Horwith M, Peterson RE, Khandji AG, Wardlaw SL. Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab. 2002;87:3084–3089.PubMedCrossRefGoogle Scholar
  86. 86.
    Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99-106. discussion 106–107.PubMedCrossRefGoogle Scholar
  87. 87.
    Jaffrain-Rea ML, Di Stefano D, Minniti G, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103–113.PubMedCrossRefGoogle Scholar
  88. 88.
    Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci. 2003;30:215–219.PubMedGoogle Scholar
  89. 89.
    Schreiber S, Saeger W, Ludecke DK. Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary. 1999;1:213–220.PubMedCrossRefGoogle Scholar
  90. 90.
    Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol. 1999;52:107–111.PubMedCrossRefGoogle Scholar
  91. 91.
    Saeger W. Pituitary tumors: prognostic indicators. Endocrine. 2005;28:57–66.PubMedCrossRefGoogle Scholar
  92. 92.
    Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res. 2004;37:235–243.PubMedCrossRefGoogle Scholar
  93. 93.
    Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res. 2002;35:561–565.PubMedGoogle Scholar
  94. 94.
    Vidal S, Kovacs K, Bell D, Horvath E, Scheithauer BW, Lloyd RV. Cyclooxygenase-2 expression in human pituitary tumors. Cancer. 2003;97:2814–2821.PubMedCrossRefGoogle Scholar
  95. 95.
    Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251–2255.PubMedGoogle Scholar
  96. 96.
    Spada A. Growth factors and human pituitary adenomas. Eur J Endocrinol. 1998;138:255–257.PubMedCrossRefGoogle Scholar
  97. 97.
    Ito M, Enomoto H, Usa T, et al. Expression of parathyroid hormone related peptide in human pituitary tumours. J Clin Pathol. 1993;46:682–683.PubMedCrossRefGoogle Scholar
  98. 98.
    Clayton RN, Farrell WE. Clonality of pituitary tumours: more complicated than initially envisaged? Brain Pathol. 2001;11:313–327.PubMedCrossRefGoogle Scholar
  99. 99.
    Bystrom C, Larsson C, Blomberg C, et al. Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA. 1990;87:1968–1972.PubMedCrossRefGoogle Scholar
  100. 100.
    Bale AE, Norton JA, Wong EL, et al. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res. 1991;51:1154–1157.PubMedGoogle Scholar
  101. 101.
    Wrocklage C, Gold H, Hackl W, Buchfelder M, Fahlbusch R, Paulus W. Increased menin expression in sporadic pituitary adenomas. Clin Endocrinol. 2002;56:589–594.CrossRefGoogle Scholar
  102. 102.
    Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature. 1987;330:566–568.PubMedCrossRefGoogle Scholar
  103. 103.
    Clementi E, Malgaretti N, Meldolesi J, Taramelli R. A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene. 1990;5:1059–1061.PubMedGoogle Scholar
  104. 104.
    Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med. 2003;228:1004–1017.Google Scholar
  105. 105.
    Boggild MD, Jenkinson S, Pistorello M, et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab. 1994;78:387–392.PubMedCrossRefGoogle Scholar
  106. 106.
    Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22:675–705.PubMedCrossRefGoogle Scholar
  107. 107.
    Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997;11:433–441.PubMedCrossRefGoogle Scholar
  108. 108.
    Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab. 1999;84:761–767.PubMedCrossRefGoogle Scholar
  109. 109.
    Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med. 1999;5:1317–1321.PubMedCrossRefGoogle Scholar
  110. 110.
    Levy A, Hall L, Yeudall WA, Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol. 1994;41:809–814.CrossRefGoogle Scholar
  111. 111.
    Herman V, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab. 1993;77:50–55.PubMedCrossRefGoogle Scholar
  112. 112.
    Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38:765-770. discussion 770–761.PubMedCrossRefGoogle Scholar
  113. 113.
    Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000;143:R1-R6.PubMedCrossRefGoogle Scholar
  114. 114.
    Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JA. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol. 2000;53:337–344.CrossRefGoogle Scholar
  115. 115.
    Cryns VL, Alexander JM, Klibanski A, Arnold A. The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab. 1993;77:644–646.PubMedCrossRefGoogle Scholar
  116. 116.
    Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 1995;55:1613–1616.PubMedGoogle Scholar
  117. 117.
    Cohen-Gadol AA, Pichelmann MA, Link MJ, et al. Granular cell tumor of the sellar and suprasellar region: clinicopathologic study of 11 cases and literature review. Mayo Clinic Proc. 2003;78:567–573.CrossRefGoogle Scholar
  118. 118.
    Luse SA, Kernohan JW. Granular cell tumors of the stalk and posterior lobe of the pituitary gland. Cancer. 1955;8:616–622.PubMedCrossRefGoogle Scholar
  119. 119.
    Vogelgesang S, Junge MH, Pahnke J, Gaab MR, Warzok RW. Sellar/suprasellar mass in a 59-year-old woman. Brain Pathol. 2002;12:136–139.Google Scholar
  120. 120.
    Nishioka H, Ii K, Llena JF, Hirano A. Immunohistochemical study of granular cell tumors of the neurophypophysis. Virchow Arch. 1991;60:413–417.CrossRefGoogle Scholar
  121. 121.
    Rickert CH, Paulus W. Genetic characterization of granular cell tumours. Acta Neuropathol. 2002;103:309–312.PubMedCrossRefGoogle Scholar
  122. 122.
    Figarella-Branger D, Dufour H, Fernandez C, Boyvier-Labbit C, Grisoli F, Pellissier JF. Pituicytoma, a mis-diagnosed benign tumor of the neurohypophysis: report of three cases. Acta Neuropathol. 2002;104:313–319.PubMedGoogle Scholar
  123. 123.
    Brat DJ, Scheithauer BW, Staugaitis SM, Cortez SC, Brecher K, Burger PC. Pituicytoma: a distinctive low-grade gloma of the neurohypophysis. Am J Surg Pathol. 2000;24:362–368.PubMedCrossRefGoogle Scholar
  124. 124.
    Kowalski RJ, Prayson RA, Mayberg MR. Pituicytoma. Ann Diagn Pathol. 2004;8:290–294.PubMedCrossRefGoogle Scholar
  125. 125.
    Kloub O, Perry A, Tu PH, Lipper M, Lopes MB. Spindle cell oncocytoma of the adenohypophysis: report of two recurrent cases. Am J Surg Pathol. 2005;29:247–253.PubMedCrossRefGoogle Scholar
  126. 126.
    Roncaroli F, Scheithauer BW, Cenacchi G, et al. Spindle cell oncocytoma of the adenohypophysis: a tumor of folliculostellate cells. Am J Surg Pathol. 2002;26:1048–1055.PubMedCrossRefGoogle Scholar
  127. 127.
    Aaberg TM Jr, Kay M, Sternau L. Metastatic tumor to the pituitary. Am J Ophtalmol. 1995;119:779–785.Google Scholar
  128. 128.
    Heshmati HM, Scheithauer BW, Young WF Jr. Metastases to the pituitary gland. Endocrinologist. 2002;12:45–49.Google Scholar
  129. 129.
    Max MB, Deck MD, Rottenberg DA. Pituitary metastasis: incidence in cancer patients and clinical differentiation from pituitary adenoma. Neurology. 1981;31:998–1002.PubMedGoogle Scholar
  130. 130.
    Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer. 1975;36:216–220.PubMedCrossRefGoogle Scholar
  131. 131.
    Kattah JC, Silgals RM, Manz H, Toro JG, Dritschilo A, Smith FP. Presentation and management of parasellar and suprasellar metastatic mass lesions. J Neurol Neurosurg Psych. 1985;48:44–49.CrossRefGoogle Scholar
  132. 132.
    Molinatti PA, Scheithauer BW, Randall RV, Laws ER Jr. Metastases to pituitary adenoma. Arch Pathol Lab Med. 1985;109:287–289.PubMedGoogle Scholar
  133. 133.
    Noga C, Prayson RA, Kowalski R, Sweeney PJ, Mayberg M. Metastatic adenocarcinoma to a pituitary adenoma: a case report and review of the literature. Ann Diagn Pathol. 2001;5:354–360.PubMedCrossRefGoogle Scholar
  134. 134.
    Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985;63:155–167.PubMedCrossRefGoogle Scholar
  135. 135.
    Poon W, Ng HK, Wong K, South JR. Primary intrasellar germinoma presenting with cavernous sinus syndrome. Surg Neurol. 1988;30:402–405.PubMedCrossRefGoogle Scholar
  136. 136.
    Nemoto K, Ohnishi Y, Tsukada T. Chronic lymphocytic leukemia showing pituitary tumor with massive leukemic cell infiltration, and special reference to clinicopathological findings of CLL. Acta Pathol Jpn. 1978;28:797–805.PubMedGoogle Scholar
  137. 137.
    Samaratunga H, Perry-Keene D, Apel RL. Primary lymphoma of pituitary gland: a neoplasm of acquired MALT? Endocr Pathol. 1997;8:335–341.PubMedCrossRefGoogle Scholar
  138. 138.
    Sanchez JA, Rahman S, Strauss RA, Kaye GI. Multiple myeloma masquerading as a pituitary tumor. Arch Pathol Lab Med. 1977;101:55–56.PubMedGoogle Scholar
  139. 139.
    Nishio S, Mizuno J, Barrow DL, Takei Y, Tindall GT. Isolated histiocytosis X of the pituitary gland: case report. Neurosurgery. 1987;21:718–721.PubMedCrossRefGoogle Scholar
  140. 140.
    Ober KP, Alexander E Jr, Challa VR, Ferree C, Elster A. Histiocytosis X of the hypothalamus. Neurosurgery. 1989;24:93–95.PubMedCrossRefGoogle Scholar
  141. 141.
    Vaquero J, Areitio E, Martinez R. Intracranial parasellar plasmacytoma. Arch Neurol. 1982;39:738.PubMedGoogle Scholar
  142. 142.
    Angiari P, Torcia E, Botticelli RA, Villani M, Merli GA, Crisi G. Ossifying parasellar chondroma. Case report. J Neurosurg Sci. 1987;31:59–63.PubMedGoogle Scholar
  143. 143.
    Asa SL, Kovacs K, Horvath E, Ezrin C, Weiss MH. Sellar glomangioma. Ultrastruct Pathol. 1984;7:49–54.PubMedCrossRefGoogle Scholar
  144. 144.
    Bots GT, Tijssen CC, Wijnalda D, Teepen JL. Alveolar soft part sarcoma of the pituitary gland with secondary involvement of the right cerebral ventricle. Br J Neurosurg. 1988;2:101–107.PubMedCrossRefGoogle Scholar
  145. 145.
    Chang WH, Khosla VK, Radotra BD, Kak VK. Large cavernous hemangioma of the pituitary fossa: a case report. Br J Neurosurg. 1991;5:627–629.CrossRefGoogle Scholar
  146. 146.
    Dan NG, Smith DE. Pituitary hemangioblastoma in a patient with von Hippel-Lindau disease. J Neurosurg. 1975;42:232–235.PubMedCrossRefGoogle Scholar
  147. 147.
    Miki K, Kawamoto K, Kawamura Y, Matsumura H, Asada Y, Hamada A. A rare case of Maffucci’s syndrome combined with tuberculum sella enchondroma, pituitary adenoma and thyroid adenoma. Acta Neurochir. 1987;87:79–85.CrossRefGoogle Scholar
  148. 148.
    Sansone ME, Liwnicz BH, Mandybur TI. Giant pituitary cavernous hemangioma: case report. J Neurosurg. 1980;53:124–126.PubMedCrossRefGoogle Scholar
  149. 149.
    Viswanathan R, Jegathraman AR, Ganapathy K, Bharati AS, Govindan R. Parasellar chondromyxofibroma with ipsilateral total internal carotid artery occlusion. Surg Neurol. 1987;28:141–144.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Christine B. Warren Baran
    • 1
  • Richard A. Prayson
    • 2
  1. 1.Cleveland Clinic Lerner College of Medicine of Case Western Reserve UniversityClevelandUSA
  2. 2.Department of Anatomic PathologyCleveland Clinic FoundationClevelandUSA

Personalised recommendations